Description
11β-Prostaglandin F2α-d9 (11β-PGF2α-d9) is intended for use as an internal standard for the quantification of 11β-PGF2α by GC- or LC-MS. 11β-PGF2α is the primary metabolite of PGD2 .1 It is formed from PGD2 via the NADPH-dependent aldo-keto reductase PGF synthase (PGFS; ） in the liver or lung.2 11β-PGF2α induces contraction of isolated cat iris sphincter, which endogenously expresses high levels of PGF2α (FP) receptors, with an EC50 value of 0.045 μM.1 It also induces contraction of isolated human bronchial smooth muscle when used at concentrations ranging from 0.1 to 30 μM.3 11β-PGF2α (0.1 and 1 μM) induces phosphorylation of ERK and CREB, as well as increases the viability of MCF-7 breast cancer cells stably expressing the FP receptor when used at concentrations of 0.1 and 1 μM.4
Uses
9α,11β-Prostaglandin F2α-d9 is the deuterium labeled 9α,11β-Prostaglandin F2α[1].
References
1. Giles, H., Bolofo, M.L., Lydford, S.J., et al. A comparative study of the prostanoid receptor profile of 9α 11 β-prostaglandin F2 and prostaglandin D2 Br. J. Pharmacol. 104(2),541-549(1991).
2. Watanabe, K. Prostaglandin F synthase Prostaglandins Other Lipid Mediat. 68-69,401-407(2002).
3. Coleman, R.A., and Sheldrick, R.L.G. Prostanoid-induced contraction of human bronchial smooth muscle is mediated by TP-receptors Br. J. Pharmacol. 96(3),688-692(1989).
4. Yoda, T., Kikuchi, K., Miki, Y., et al. 11β-Prostaglandin F2α, a bioactive metabolite catalyzed by AKR1C3, stimulates prostaglandin F receptor and induces slug expression in breast cancer Mol. Cell. Endocrinol. 413,236-247(2015).
